Literature DB >> 18408216

Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I.

Jennifer S Hackbarth1, Marina Galvez-Peralta, Nga T Dai, David A Loegering, Kevin L Peterson, Xue W Meng, Larry M Karnitz, Scott H Kaufmann.   

Abstract

Human DNA topoisomerase I (topo I) is an essential mammalian enzyme that regulates DNA supercoiling during transcription and replication. In addition, topo I is specifically targeted by the anticancer compound camptothecin and its derivatives. Previous studies have indicated that topo I is a phosphoprotein and that phosphorylation stimulates its DNA relaxation activity. The locations of most topo I phosphorylation sites have not been identified, preventing a more detailed examination of this modification. To address this issue, mass spectrometry was used to identify four topo I residues that are phosphorylated in intact cells: Ser(10), Ser(21), Ser(112), and Ser(394). Immunoblotting using anti-phosphoepitope antibodies demonstrated that these sites are phosphorylated during mitosis. In vitro kinase assays demonstrated that Ser(10) can be phosphorylated by casein kinase II, Ser(21) can be phosphorylated by protein kinase Calpha, and Ser(112) and Ser(394) can be phosphorylated by Cdk1. When wild type topo I was pulled down from mitotic cells and dephosphorylated with alkaline phosphatase, topo I activity decreased 2-fold. Likewise, topo I polypeptide with all four phosphorylation sites mutated to alanine exhibited 2-fold lower DNA relaxation activity than wild type topo I after isolation from mitotic cells. Further mutational analysis demonstrated that Ser(21) phosphorylation was responsible for this change. Consistent with these results, wild type topo I (but not S21A topo I) exhibited increased sensitivity to camptothecin-induced trapping on DNA during mitosis. Collectively these results indicate that topo I is phosphorylated during mitosis at multiple sites, one of which enhances DNA relaxation activity in vitro and interaction with DNA in cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408216      PMCID: PMC2423254          DOI: 10.1074/jbc.M802246200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

Authors:  P Pourquier; J L Waltman; Y Urasaki; N A Loktionova; A E Pegg; J L Nitiss; Y Pommier
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

2.  Reutilization of immunoblots after chemiluminescent detection.

Authors:  S H Kaufmann
Journal:  Anal Biochem       Date:  2001-09-15       Impact factor: 3.365

Review 3.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 4.  Cellular roles of DNA topoisomerases: a molecular perspective.

Authors:  James C Wang
Journal:  Nat Rev Mol Cell Biol       Date:  2002-06       Impact factor: 94.444

Review 5.  Topoisomerase II: its functions and phosphorylation.

Authors:  S M Gasser; R Walter; Q Dang; M E Cardenas
Journal:  Antonie Van Leeuwenhoek       Date:  1992-08       Impact factor: 2.271

6.  A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.

Authors:  A L Blajeski; T J Kottke; S H Kaufmann
Journal:  Exp Cell Res       Date:  2001-11-01       Impact factor: 3.905

Review 7.  Ultraviolet-B irradiation and matrix metalloproteinases: from induction via signaling to initial events.

Authors:  Peter Brenneisen; Helmut Sies; Karin Scharffetter-Kochanek
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

8.  A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.

Authors:  D M Keller; X Zeng; Y Wang; Q H Zhang; M Kapoor; H Shu; R Goodman; G Lozano; Y Zhao; H Lu
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

9.  A novel nuclear localization signal in human DNA topoisomerase I.

Authors:  Y Y Mo; C Wang; W T Beck
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

10.  Antitumour drugs impede DNA uncoiling by topoisomerase I.

Authors:  Daniel A Koster; Komaraiah Palle; Elisa S M Bot; Mary-Ann Bjornsti; Nynke H Dekker
Journal:  Nature       Date:  2007-06-24       Impact factor: 49.962

View more
  10 in total

1.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

2.  Interleukin-2 induces the activities of DNA topoisomerase I and DNA topoisomerase II in HuT 78 cells.

Authors:  Minh-Hieu Pham; Navya Kondapalli; Calvin L Reckord; P David Foglesong
Journal:  Biochem Biophys Res Commun       Date:  2009-10-08       Impact factor: 3.575

3.  Swapping of The N-Terminal Domain of Human Topoisomerase 1B with the Corresponding Plasmodium Falciparum Counterpart Strongly Impairs Enzyme Activity.

Authors:  Jagadish Babu Dasari; Bini Chhetri Soren; Alessio Ottaviani; Cinzia Tesauro; Simona Marino; Beatrice Messina; Paola Fiorani
Journal:  Rep Biochem Mol Biol       Date:  2020-01

4.  Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.

Authors:  Euphemia Leung; Gordon W Rewcastle; Wayne R Joseph; Rhonda J Rosengren; Lesley Larsen; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2011-11-22       Impact factor: 3.850

5.  Phosphorylation of Ubc9 by Cdk1 enhances SUMOylation activity.

Authors:  Yee-Fun Su; Tsunghan Yang; Hoting Huang; Leroy F Liu; Jaulang Hwang
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

Review 6.  Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.

Authors:  Mary-Ann Bjornsti; Scott H Kaufmann
Journal:  F1000Res       Date:  2019-09-30

7.  The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.

Authors:  Keya Bandyopadhyay; Pingchuan Li; Ruth A Gjerset
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

8.  CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.

Authors:  Keya Bandyopadhyay; Pingchuan Li; Ruth A Gjerset
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan.

Authors:  M C Díaz de la Loza; R E Wellinger
Journal:  Nucleic Acids Res       Date:  2009-01-16       Impact factor: 16.971

10.  Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma.

Authors:  Yeonhwa Song; Sanghwa Kim; Hyeryon Lee; Joo Hwan No; Hyung Chul Ryu; Jason Kim; Jee Woong Lim; Moonhee Kim; Inhee Choi; Haeng Ran Seo
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.